Second, in AD-like tauopathy hTau mice, which develops age-related tau pathologies and neurodegeneration, cis mAb (300 μg per mouse, intraperitoneally (i.p.)for the first 4 months, followed by every other week treatment) prevents formation of cis P-tau, tangles, neurodegeneration, demyelination and impairment in working memory and spatial learning/memory (Qiu et al., 2021). Here, MAPT is linked to tauopathy.